(Q50250939)

28 February 2018

title

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. (English)

1 reference

28 February 2018

1 reference

3

Bernard Escudier

1 reference

28 February 2018

2

Karim Fizazi

1 reference

28 February 2018

1

Dominique Prapotnich

1 reference

28 February 2018

Nathalie Cathala

series ordinal

5

object named as

Nathalie Cathala

1 reference

28 February 2018

Annick Mombet

series ordinal

4

object named as

Annick Mombet

1 reference

28 February 2018

author name string

Guy Vallancien

series ordinal

6

1 reference

28 February 2018

language of work or name

English

0 references

publication date

1 March 2003

1 reference

28 February 2018

published in

European Urology

1 reference

28 February 2018

volume

43

1 reference

28 February 2018

issue

3

1 reference

28 February 2018

page(s)

233-39; discussion 239-40

1 reference

28 February 2018

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Osteoporosis due to androgen deprivation therapy in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression in the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Current status of intermittent androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent complete androgen blockade in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

[Advances in surgical techniques and results of radical cystectomies for bladder cancer. 106 patients]

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900004-6

7 January 2021

10.1016/S0302-2838(03)00004-6

Identifiers

DOI

1 reference

28 February 2018

1 reference

28 February 2018